Gen-Probe requests US approval of Procleix Ultrio for hepatitis B virus screening
This article was originally published in Clinica
Gen-Probe has applied to the US FDA for approval to use its Procleix Ultrio assay to screen donated blood for the hepatitis B virus (HBV). The San Diego, California company has submitted a supplemental biologics licence application (BLA) to use the assay to screen for HBV on both its semi-automated instrument platform and on the fully automated, high-throughput Tigris system. The FDA approved Procleix Ultrio to screen donated blood for HIV-1 and the hepatitis C virus (HCV) in late 2006. According to the World Health Organisation, more than 350 million people worldwide are chronically infected with HBV, with more than one million dying every year from the disease. Gen-Probe's blood screening products are marketed worldwide by Chiron, a subsidiary of pharma giant Novartis.
You may also be interested in...
Hours before the US FDA confirmed the first drug shortage due to active pharmaceutical ingredient constraints because of the coronavirus situation in China, generics industry leader Mylan came under pressure about the potential impact on its business.
Government advisory committee gives initial nod to what will become Japan’s most expensive single drug, but reimbursement pricing could come in for close scrutiny.
Laparoscopic power morcellation to remove uterine fibroids should only be performed with the use of a compatible containment system, and only on women younger than 50, the US FDA said in a newly published safety communication and draft guidance document. See what the president of the gynecologic trade group AAGL, Jubilee Brown, said about it here.